Clinical Trial Update: Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating arzoxifene for fracture reduction and incidence of breast cancer in postmenopausal osteoporosis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Osteoporosis

Drugs mentioned

• Arzoxifene (arzoxifene)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Osteoporosis, Postmenopausal | Phase 3 | Status: COMPLETED